Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) [Phase 3]

View source ↗

Summary

Phase 3 trial of pembrolizumab with etoposide and platinum in extensive-stage small cell lung cancer has completed, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CISPLATIN (cisplatin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Small Cell Lung Cancer (SCLC) | Phase 3 | Status: COMPLETED | Results posted: 2020-12-22